Phase II study of computed tomography-guided 125I-seed implantation plus chemotherapy for locally recurrent rectal cancer

CTII plus FOLFIRI improves the LCT with tolerable toxicities as a second-line treatment in patients with local recurrent rectal cancer, and is helpful to prolong the OS, particularly in patients without distant metastases or with a history of radiotherapy.